Aptinyx — Technical Presentation (October 2020)
24 slides from Aptinyx's technical presentation, Oct 20, 2020
Slide 1: Phase 2 PTSD Study Top-Line Results
Phase 2 PTSD Study Top - Line Results October 20, 2020
Slide 2: This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the
This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informat ion al purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securitie s i n any state or
Slide 3: PTSD
PTSD October 20, 2020 3 both approved ~ 20+ years ago ONLY 2 APPROVED THERAPIES with an estimated lifetime prevalence of 6.8% people suffering from PTSD in the U.S. ~ 8.5 MILLION Numerous causes of PTSD Car accidents Criminal assault War combat Natural disaster Sexual trauma 50 - 66 % also battle si
Slide 4: Differentiated Approach to Targeting PTSD
ANTIDEPRESSANTS – Mood ANXIOLYTICS – Severe anxiety - related complications HYPNOTICS – Nightmares – Sleep disturbances Differentiated Approach to Targeting PTSD: Addressing the Underlying Learning & Memory Dysfunction October 20, 2020 4 CURRENT APPROACHES Target symptoms OUR APPROACH Targets underl
Slide 5: PTSD Symptoms and Diagnosis
PTSD Symptoms and Diagnosis Characterized by Four Core Symptom Clusters Captured in the CAPS - 5 October 20, 2020 5 Along with these symptom clusters, a diagnosis of PTSD typically requires: • Symptoms for ≥ 1 month • Symptoms cause impairment in important areas of function Arousal & Reactivity • Ju
Slide 6: Study Design, Subject Disposition, and Baseline Characteristics
Study Design, Subject Disposition, and Baseline Characteristics October 20, 2020 6
Slide 7: First-in-Patient Exploratory Phase 2 Study in PTSD
STUDY OBJECTIVE Inform future development with regard to: First - in - Patient Exploratory Phase 2 Study of NYX - 783 in PTSD Important First Step in Evaluating the Efficacy of a Novel Mechanism 7 PHASE 1 PRECLINICAL PHASE 2 (FIRST - IN - PATIENT) Patient inclusion/exclusion criteria Endpoints Antic
Slide 8: Phase 2 PTSD Study Design
Phase 2 PTSD Study Design Pre - Specified Primary Objective: To assess efficacy of NYX - 783 in a PTSD population using CAPS - 5 total score and CAPS - 5 symptom cluster scores October 20, 2020 8 Placebo non - responders SCREENING ( 2 – 4 WEEKS) STAGE 1 (4 WEEKS) STAGE 2 (4 WEEKS) Diagnosis of PTSD
Slide 9: Baseline Demographics
Baseline Demographics Stage 1 Stage 2 Demographic Placebo (n=103) 10 mg NYX - 783 (n=24) 50 mg NYX - 783 (n=26) Total (n=153) Placebo Only (n=38) Placebo Stage 2 (n=38) 10 mg NYX - 783 (n=22) 50 mg NYX - 783 (n=26) Total (n=124) Age Mean 40.8 43.4 43.8 41.7 43.6 44.7 37.9 39.8 42.1 Gender, n (%) Mal
Slide 10: Baseline Clinical Characteristics – ITT Primary Efficacy Population
Baseline clinical characteristics are consistent with a moderate to severe PTSD patient population Baseline Clinical Characteristics – ITT Primary Efficacy Population Stage 1 Stage 2 (PBO Non - Responders) Demographic Placebo (n=103) 10 mg NYX - 783 (n=24) 50 mg NYX - 783 (n=26) Total (n=153) Placeb
Slide 11: Efficacy Data
Efficacy Data October 20, 2020 11
Slide 12: Primary Objectives: CAPS-5 Arousal and Reactivity Score
Clinically meaningful and statistically significant improvement on CAPS - 5 Arousal and Reactivity Score for 10mg, 50mg, and pooled dose groups Effect is concordant with fear extinction mechanism of NYX - 783 Significant improvement on Arousal and Reactivity symptom domain largely drove overall tren
Slide 13: Primary Objectives: CAPS-5 Negative Cognitions and Mood Score
P - values versus PBO 10mg 50mg Pooled P - values versus PBO 10mg 50mg Pooled Stage 1 NS 0.049 NS Stage 2 NS NS NS Stage 1 + Stage 2 (primary analysis) NS 0.138 NS Trend to significance in combined Stage 1+2 analysis for 50mg dose Statistically significant improvement in Negative Cognitions and Mood
Slide 14: Primary Objectives: CAPS-5 Total Score
Trend to significance in combined Stage 1+2 analysis for 50mg dose Robust and clinically meaningful reduction in CAPS - 5 Total Score from baseline during Stage 1 for 50mg dose – trend to significance despite strong placebo effect Reduction in CAPS - 5 Total Score during Stage 2 for 10mg and 50mg St
Slide 15: CAPS-5 Total Score – Responder Analysis
44% 26% 45% 30% 78% 50% ≥30% ≥50% Improvement from Baseline on CAPS - 5 Total Score Proportion of Patients Achieving Key Response Thresholds @ Week 4 Placebo (n=85) 10mg NYX-783 (n=20) 50mg NYX-783 (n=18) p=0.008 vs. PBO p=0.044 vs. PBO Analysis inclusive of ITT patients in with CAPS - 5 Total Score
Slide 16: Additional Pre-Specified Endpoints: HADS-Anxiety
P - values versus PBO 10mg 50mg Pooled P - values versus PBO 10mg 50mg Pooled Stage 1 0.024 0.018 0.004 Stage 2 0.067 NS NS Stage 1 + Stage 2 (primary analysis) 0.045 0.166 0.056 Strong effect on HADS - Anxiety scale – statistically significant for 10mg and pooled doses, trending for 50mg HADS - Anx
Slide 17: Additional Pre-Specified Endpoints: PCL-5 (Patient Reported)
P - values versus PBO 10mg 50mg Pooled P - values versus PBO 10mg 50mg Pooled Stage 1 NS 0.0987 NS Stage 2 0.138 NS NS Stage 1 + Stage 2 (primary analysis) NS 0.170 0.180 PCL - 5 is a patient response endpoint with symptom questions identical to CAPS - 5 Trend to significance for 50mg and pooled dos
Slide 18: Tolerability and Adverse Event Data
Tolerability and Adverse Event Data October 20, 2020 18
Slide 19: Favorable Tolerability and Adverse Event Profile Observed
Favorable Tolerability and Adverse Event Profile Observed Safety Population 19 October 20, 2020 Treatment Emergent Adverse Events (TEAE) Placebo Only (N=102) n (%) NYX - 783 10 mg (N=24) n (%) NYX - 783 50 mg (N=26) n (%) Total (N=152) n (%) Placebo Only (N=38) n (%) Placebo Stage 2 (N=36) n (%) NYX
Slide 20: Other Adverse Event and Tolerability Observations
No fatal adverse events No life - threatening adverse events No drug - related serious adverse events – 3 reports of suicidal ideation in the study o 2 on placebo o 1 on NYX - 783 – deemed by investigator to be unrelated to study drug No drug - related severe adverse events No signal of clinically m
Slide 21: Clinician's Perspective: PTSD
Murray Stein, MD, MPH Distinguished Professor of Psychiatry and Public Health University of California San Diego 21 Clinician’s Perspective: PTSD Staff Psychiatrist at the VA San Diego Healthcare System October 20, 2020 DSM - 5 Anxiety, Obsessive - Compulsive Spectrum, Posttraumatic, and Dissociativ
Slide 22: Advancing a Leading Pipeline of CNS Therapies
Approximate cash balance of $116 mm as of June 30, 2020, is expected to provide operational runway into 2022 INDICATION PRECLINICAL/ IND ENABLING PHASE 1 PHASE 2 PHASE 3 REGISTRATION/ COMMERCIAL CHRONIC PAIN FRANCHISE NYX - 2925 Fibromyalgia Painful Diabetic Peripheral Neuropathy PSYCHIATRY FRANCHIS
Slide 23: Q&A
Q&A October 20, 2020 23
Slide 24: Summary of Top-line Results
Robust, statistically significant, clinically meaningful, mechanistically relevant effects observed on numerous efficacy endpoints with only 4 weeks of treatment Clear dose response: 50mg dose demonstrated better effect than 10mg dose Majority of patients in the 50mg group demonstrated clinically me